HRP20210832T1 - Kombinacija trazodona i gabapentina za liječenje boli - Google Patents
Kombinacija trazodona i gabapentina za liječenje boli Download PDFInfo
- Publication number
- HRP20210832T1 HRP20210832T1 HRP20210832TT HRP20210832T HRP20210832T1 HR P20210832 T1 HRP20210832 T1 HR P20210832T1 HR P20210832T T HRP20210832T T HR P20210832TT HR P20210832 T HRP20210832 T HR P20210832T HR P20210832 T1 HRP20210832 T1 HR P20210832T1
- Authority
- HR
- Croatia
- Prior art keywords
- gabapentin
- amount
- salt
- prodrug
- equal
- Prior art date
Links
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title claims 38
- 229960002870 gabapentin Drugs 0.000 title claims 19
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 title claims 12
- 229960003991 trazodone Drugs 0.000 title claims 12
- 208000002193 Pain Diseases 0.000 title claims 5
- 150000003839 salts Chemical class 0.000 claims 16
- 229940002612 prodrug Drugs 0.000 claims 15
- 239000000651 prodrug Substances 0.000 claims 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 229960002359 gabapentin enacarbil Drugs 0.000 claims 7
- TZDUHAJSIBHXDL-UHFFFAOYSA-N gabapentin enacarbil Chemical compound CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 TZDUHAJSIBHXDL-UHFFFAOYSA-N 0.000 claims 7
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000011885 synergistic combination Substances 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (11)
1. Farmaceutski pripravak, naznačen time, da obuhvaća sinergističku kombinaciju trazodona ili njegove soli u količini za dobivanje odgovarajuće doze koja je jednaka ili manja od 1 mg/kg, i gabapentina ili njegove soli ili njegovog predlijeka u količini za dobivanje doze koja je jednaka ili manja od 15 mg/kg, te najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo, za uporabu u liječenju boli, pri čemu se navedena bol bira iz skupine koju čine kronična bol, upalna bol i neuropatska bol, gdje spomenuti trazodon i spomenuti gabapentin ostvaruju maseni omjer trazodona prema gabapentinu u rasponu od 1:15 do 1:5 i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
2. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini u količini za dobivanje odgovarajuće doze koja je jednaka ili manja od 0,5 mg/kg i gabapentin ili njegovu sol ili njegov predlijek u količini u količini za dobivanje odgovarajuće doze koja je jednaka ili manja od 5 mg/kg.
3. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini u količini za dobivanje odgovarajuće doze koja je jednaka ili manja od 0,2 mg/kg i gabapentin ili njegovu sol ili njegov predlijek u količini u količini za dobivanje odgovarajuće doze koja je jednaka ili manja od 2 mg/kg i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
4. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini u količini za dobivanje odgovarajuće doze koja je jednaka iznosu oko 0,15 mg/kg i gabapentin ili njegovu sol ili njegov predlijek u količini u količini za dobivanje odgovarajuće doze koja je jednaka iznosu oko 1,5 mg/kg i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
5. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini koja je jednaka ili manja od 70 mg i gabapentin ili njegovu sol ili njegov predlijek u količini koja je jednaka ili manja od 1000 mg i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
6. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini koja je jednaka ili manja od 35 mg i gabapentin ili njegovu sol ili njegov predlijek u količini koja je jednaka ili manja od 350 mg i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
7. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini koja je jednaka ili manja od 15 mg i gabapentin ili njegovu sol ili njegov predlijek u količini koja je jednaka ili manja od 150 mg i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
8. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 7, naznačen time, da navedeni pripravak sadrži količinu trazodona ili njegove soli i količinu gabapentina ili njegove soli ili njegovog predlijeka, tako da se ostvaruje maseni omjer trazodona prema gabapentinu u rasponu od oko 1:10 i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
9. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 8, naznačen time, da služi u liječenju kronične boli.
10. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 8, naznačen time, da je navedena upalna bol izazvana putem edema, eritema, zglobne upale, osteoartritisa, reumatoidnog artritisa i artroze.
11. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 8, naznačen time, da je navedena neuropatska bol izazvana putem dijabetesa, raka, imunodeficijencije, ozljede, ishemije, multiple skleroze, išijasa, trigeminalne neuralgije, fibromialgije i postherpetičnog sindroma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15191024 | 2015-10-22 | ||
| PCT/EP2016/074835 WO2017067870A1 (en) | 2015-10-22 | 2016-10-17 | Combination of trazodone and gabapentin for the treatment of pain |
| EP16781816.0A EP3364975B1 (en) | 2015-10-22 | 2016-10-17 | Combination of trazodone and gabapentin for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210832T1 true HRP20210832T1 (hr) | 2021-08-06 |
Family
ID=54345445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210832TT HRP20210832T1 (hr) | 2015-10-22 | 2021-05-24 | Kombinacija trazodona i gabapentina za liječenje boli |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10786498B2 (hr) |
| EP (2) | EP3364975B1 (hr) |
| JP (1) | JP6924184B2 (hr) |
| KR (1) | KR102691296B1 (hr) |
| CN (1) | CN108174599B (hr) |
| AR (1) | AR106415A1 (hr) |
| AU (1) | AU2016341063B2 (hr) |
| BR (1) | BR112018007374B1 (hr) |
| CA (1) | CA2999389C (hr) |
| CY (1) | CY1124229T1 (hr) |
| DK (1) | DK3364975T3 (hr) |
| EA (2) | EA037838B1 (hr) |
| ES (1) | ES2879392T3 (hr) |
| GE (1) | GEP20207145B (hr) |
| HK (1) | HK1252359A1 (hr) |
| HR (1) | HRP20210832T1 (hr) |
| HU (1) | HUE054653T2 (hr) |
| IL (1) | IL258316B (hr) |
| LT (1) | LT3364975T (hr) |
| MD (1) | MD3364975T2 (hr) |
| MX (1) | MX2018004532A (hr) |
| PL (1) | PL3364975T3 (hr) |
| PT (1) | PT3364975T (hr) |
| RS (1) | RS61989B1 (hr) |
| SI (1) | SI3364975T1 (hr) |
| UA (1) | UA122245C2 (hr) |
| WO (1) | WO2017067870A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201900006602A1 (it) * | 2019-05-07 | 2020-11-07 | Acraf | Composizione farmaceutica per il trattamento del dolore neuropatico |
| EP3907214A1 (en) * | 2020-05-04 | 2021-11-10 | Dompe' Farmaceutici S.P.A. | Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060087560A (ko) * | 2003-09-12 | 2006-08-02 | 워너-램버트 캄파니 엘엘씨 | 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물 |
| DE602004024317D1 (de) | 2003-09-12 | 2010-01-07 | Pfizer | Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern |
| WO2006069293A2 (en) * | 2004-12-22 | 2006-06-29 | Friedman Robert S | Composition comprising n-acetylcysteine and further pain or anti- inflamm medications |
| US20120083508A1 (en) * | 2006-12-22 | 2012-04-05 | Allergan, Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
| WO2009012058A2 (en) * | 2007-07-18 | 2009-01-22 | Dow Global Technologies Inc. | Water-glycol hydraulic fluid compositions |
| US10300031B2 (en) | 2007-08-06 | 2019-05-28 | Trinity Laboratories Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| KR20110028320A (ko) * | 2008-07-02 | 2011-03-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 가바펜틴 에나카르빌 염 및 이의 제조 방법 |
| JP5893135B2 (ja) | 2011-06-28 | 2016-03-23 | ビボゾーン インコーポレイテッド | 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途 |
-
2016
- 2016-10-17 JP JP2018519360A patent/JP6924184B2/ja active Active
- 2016-10-17 HU HUE16781816A patent/HUE054653T2/hu unknown
- 2016-10-17 DK DK16781816.0T patent/DK3364975T3/da active
- 2016-10-17 PT PT167818160T patent/PT3364975T/pt unknown
- 2016-10-17 EA EA201890911A patent/EA037838B1/ru unknown
- 2016-10-17 BR BR112018007374-1A patent/BR112018007374B1/pt active IP Right Grant
- 2016-10-17 IL IL258316A patent/IL258316B/en unknown
- 2016-10-17 UA UAA201804930A patent/UA122245C2/uk unknown
- 2016-10-17 CA CA2999389A patent/CA2999389C/en active Active
- 2016-10-17 AU AU2016341063A patent/AU2016341063B2/en active Active
- 2016-10-17 ES ES16781816T patent/ES2879392T3/es active Active
- 2016-10-17 MX MX2018004532A patent/MX2018004532A/es unknown
- 2016-10-17 EP EP16781816.0A patent/EP3364975B1/en active Active
- 2016-10-17 MD MDE20180825T patent/MD3364975T2/ro unknown
- 2016-10-17 CN CN201680059627.1A patent/CN108174599B/zh active Active
- 2016-10-17 PL PL16781816T patent/PL3364975T3/pl unknown
- 2016-10-17 GE GEAP201614778A patent/GEP20207145B/en unknown
- 2016-10-17 EP EP21158825.6A patent/EP3881845A3/en active Pending
- 2016-10-17 WO PCT/EP2016/074835 patent/WO2017067870A1/en active Application Filing
- 2016-10-17 LT LTEP16781816.0T patent/LT3364975T/lt unknown
- 2016-10-17 SI SI201631218T patent/SI3364975T1/sl unknown
- 2016-10-17 EA EA202190626A patent/EA202190626A3/ru unknown
- 2016-10-17 US US15/767,543 patent/US10786498B2/en active Active
- 2016-10-17 RS RS20210740A patent/RS61989B1/sr unknown
- 2016-10-17 KR KR1020187013499A patent/KR102691296B1/ko active IP Right Grant
- 2016-10-20 AR ARP160103200A patent/AR106415A1/es unknown
-
2018
- 2018-09-11 HK HK18111645.6A patent/HK1252359A1/zh unknown
-
2020
- 2020-04-15 US US16/849,545 patent/US11752147B2/en active Active
-
2021
- 2021-05-24 HR HRP20210832TT patent/HRP20210832T1/hr unknown
- 2021-06-18 CY CY20211100546T patent/CY1124229T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210832T1 (hr) | Kombinacija trazodona i gabapentina za liječenje boli | |
| HRP20200600T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| EP4218819A3 (en) | Combination therapy based on pd-1 signal inhibitors | |
| FI3355889T3 (fi) | Diaminopyrimidiini-p2x3- ja p2x2/3-reseptorimodulaattoreita käytettäväksi yskän hoidossa | |
| HRP20160203T1 (hr) | Pripravci koji sadrže 15-hepe i postupci njihove upotrebe | |
| HRP20210552T1 (hr) | Liječenje multiplog mijeloma (mm) | |
| WO2013100882A3 (en) | Combinations of diacerein and non-steroidal inflammation drugs | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| HRP20220903T1 (hr) | Seladelpar za liječenje primarnog bilijarnog kolangitisa | |
| MX2018001014A (es) | Sales y profarmacos de 1-metil-d-triptofano. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| JP2017512194A5 (hr) | ||
| JP2017507142A5 (hr) | ||
| HRP20201233T1 (hr) | Spoj izveden od pirazolina i njegova primjena u tjednom doznom režimu protiv upale i bola porijeklom od degenerativnog oboljenja zgloba kod sisavaca | |
| WO2015152577A3 (ko) | 골 질환 예방 및 치료용 조성물 | |
| RU2016149776A (ru) | ЛЕЧЕНИЕ ИММУННЫХ, ВОСПАЛИТЕЛЬНЫХ И ДЕГЕНЕРАТИВНЫХ АРТРИТОВ С ПОМОЩЬЮ ОЛОВА-117m | |
| MX2016010892A (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica. | |
| WO2017106367A8 (en) | Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity | |
| BR112017022856A2 (pt) | combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas | |
| MX348595B (es) | Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion. | |
| BR112017022335A2 (pt) | combinação de dose fixa inviolável que fornece rápida liberação de dois fármacos a partir de partículas e matriz | |
| WO2015166418A3 (es) | Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
| WO2019132729A3 (ru) | Фармацевтические композиции на основе ментилового эфира индометацина и его применение | |
| MX2018011685A (es) | Proceso para formulaciones solidas de mesalazina. | |
| MX2018011142A (es) | Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona. |